Inflammatory Signal Inhibitors for COVID-19 (MATIS)

Conditions:   Coronavirus;   Covid19;   Pneumonia Interventions:   Drug: Ruxolitinib;   Drug: Fostamatinib;   Other: Standard of care Sponsors:   Imperial College London;   Imperial College Healthcare NHS Trust;   Rigel Pharmaceuticals;   Novartis Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Authors: Yamaya T, Baba T, Hagiwara E, Ikeda S, Niwa T, Kitayama T, Murohashi K, Higa K, Sato Y, Ogura T Abstract Coronavirus disease 2019 (COVID-19) has been recognized as a worldwide pandemic. However, the clinical course of COVID-19 remains poorly characterized. Although some cases of pneumothorax have been reported, they all had pulmonary complications or were managed with mechanical ventilation. We herein report a case of pneumothorax that developed even though the patient had no pulmonary underlying diseases and had never been managed with mechanical ventilation. In the present case, a lung bulla was found on...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Comparison of deaths from the coronavirus (COVID-19) with deaths from influenza (flu) and pneumonia. Includes deaths by date of death occurrence and breakdowns by sex and age.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
Conclusion: The ADE (adverse drug event) signal detection based on FAERS is helpful to clarify the potential adverse events related to ribavirin-interferon combination for novel coronavirus therapy; clinicians should pay attention to the adverse reactions of gastrointestinal and blood systems, closely monitor the fluctuations of the platelet count, and carry out necessary mental health interventions to avoid serious adverse events. PMID: 33029193 [PubMed - in process]
Source: Computational and Mathematical Methods in Medicine - Category: Statistics Tags: Comput Math Methods Med Source Type: research
Authors: Chen X, Yin YH, Zhang MY, Liu JY, Li R, Qu YQ Abstract ShuFeng JieDu capsule (SFJDC), a traditional Chinese medicine, has been recommended for the treatment of COVID-19 infections. However, the pharmacological mechanism of SFJDC still remains vague to date. The active ingredients and their target genes of SFJDC were collected from TCMSP. COVID-19 is a type of Novel Coronavirus Pneumonia (NCP). NCP-related target genes were collected from GeneCards database. The ingredients-targets network of SFJDC and PPI networks were constructed. The candidate genes were screened by Venn diagram package for enrichment an...
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
Authors: Batista RCS, Arruda CVB, Cassimiro M, Gominho L, Moura AC, Albuquerque DS, Romeiro K Abstract As early as December 2019 in the province of Hubei, China, contamination of patients with pneumonia of an unknown etiology occurred. These patients presented with symptoms such as coughing, sore throat, malaise, diarrhea, high fever, and dyspnea. This emerging disease was named COVID-19 due to being part of the group of coronaviruses (CoVs) belonging to the subfamily Orthocoronavirinae, in the Coronaviridae family and in the Nidovirales order. COVID-19 is most commonly transmitted through speech, coughing, sneezin...
Source: The Scientific World Journal - Category: Science Tags: ScientificWorldJournal Source Type: research
Since the appearance of the novel coronavirus (severe acute respiratory syndrome-coronavirus-2) and related coronavirus disease 2019 (COVID-19) in China in December 2019, a very high number of small and large patient series have been published in literature from around the world. Even though the classical presentation of COVID-19 is one with respiratory symptoms with or without pneumonia that can be self-limiting or evolve into severe respiratory distress syndrome with multiple organ failure, and secondary bacterial sepsis, a large body of evidence suggests a plethora of other types of clinical presentation. In this exhaus...
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
Conditions:   Coronavirus;   Covid19;   Pneumonia Interventions:   Drug: Ruxolitinib;   Drug: Fostamatinib;   Other: Standard of care Sponsors:   Imperial College London;   Imperial College Healthcare NHS Trust;   Rigel Pharmaceuticals;   Novartis Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In a report published Oct. 8 in the New England Journal of Medicine, researchers confirmed the benefits of remdesivir for treating people hospitalized for COVID-19. Remdesivir, an antiviral drug, has emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for treating anyone hospitalized for COVID-19. That authorization means that doctors can prescribe the intravenous (IV) drug for people who are infected with SARS-CoV-2 and have been hospitalized. While the drug was initially authorized only for those who needed supplemental oxygen or ventilators to breathe, an expanded EUA from the FDA in late ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
ConclusionsDespite a rapid worldwide spread, attack rates have been low in most regions, demonstrating the efficacy of control measures.
Source: Infection - Category: Infectious Diseases Source Type: research
In this study, we investigated a COVID-19 cohort in Shanghai, China. We screened viruses include Human parainfluenza virus 1, Human parainfluenza virus 2, Human parainfluenza virus 3, Human parainfluenza virus4, Influenza A virus, Influenza B virus, Human rhinovirus, Human metapneumovirus, Human respiratory syncytial virus, Human Bocavirus, Human adenovirus, Human Coronavirus 229E, Human Coronavirus NL63, Human Coronavirus HKU1, Human Coronavirus OC43; bacteria include Pseudomonas aeruginosa, Moraxella catarrhalis, Mycobacterium tuberculosis, Legionella pneumophila, Group A Streptococcus, Haemophilus influenza, Staphylococ...
Source: Journal of Infection - Category: Infectious Diseases Authors: Tags: Letter to the Editor Source Type: research
More News: Coronavirus | COVID-19 | Pneumonia | Research